Vanda Pharmaceuticals Inc. (VNDA), a biopharmaceutical company, announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted Imsidolimab orphan drug designation for the treatment of generalized pustular psoriasis.
Generalized pustular psoriasis or GPP is a rare but serious autoinflammatory disease. It causes pustules on inflamed skin patches and without treatment it can lead to severe and potentially fatal complications. (clevelandclinic.org). The firm estimates that in Japan it affects approximately 2,200 people.
Imsidolimab is designed to inhibit interleukin-36 (IL-36) receptor signalling and addresses the deficiency in the endogenous IL-36 receptor antagonist regulator observed in patients with GPP.
Orphan Drug designation provides development incentives, including subsidies for research and development cost and a potential market exclusivity up to 10 years following approval.
VNDA closed Wednesday's trade at $6.46 up 3.86%. In the afterhours the stock is trading at $6.54, up 1.24%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.